> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Orphan Status for Ebola-like Vaccine
- URL: https://www.fdaweb.com/orphan-status-for-ebola-like-vaccine/
- Published: 2024-04-15T12:00:00.000Z
- Updated: 2026-09-14T14:28:17.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156780

FDA has granted Soligenix an orphan drug designation for the active ingredient in MarVax, the subunit protein vaccine of recombinantly expressed *Marburg marburgvirus* (MARV) glycoprotein for post-exposure prophylaxis against MARV infection. *Marburg marburgvirus* causes Marburg Virus Disease, a related disease to the Ebola virus disease, the company says. “Although MARV has caused fewer outbreaks, they remain highly fatal and a significant risk in continental Africa, with the most recent outbreak occurring in 2023.”

Subunit vaccines are described in a company release as a gold standard technology for safety, and they are also broadly applicable across the population, especially when combined with an effective adjuvant.